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Abstract
The coronavirus disease 2019 (COVID-19) outbreak started in China in December 2019 and has developed into 
a pandemic. Using mandatory large-scale public health interventions including a lockdown with locally varying 
intensity and duration, China has been successful in controlling the epidemic at an early stage. The epicentre of 
the pandemic has since shifted to Europe and The Americas. In certain cities and regions, health systems became 
overwhelmed by high numbers of cases and deaths, whereas other regions continue to experience low incidence 
rates. Still, lockdowns were usually implemented country-wide, albeit with differing intensities between 
countries. Compared to its neighbours, Germany has managed to keep the epidemic relatively well under 
control, in spite of a lockdown that was only partial. In analogy to many countries at a similar stage, Germany 
is now under increasing pressure to further relax lockdown measures to limit economic and psychosocial costs. 
However, if this is done too rapidly, Germany risks facing tens of thousands more severe cases of COVID-19 
and deaths in the coming months. Hence, it could again follow China’s example and relax measures according to 
local incidence, based on intensive testing.
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Introduction
In December 2019, a pandemic of coronavirus disease 2019 
(COVID-19) began, caused by the severe acute respiratory 
syndrome virus (SARS-CoV-2).1-3 The World Health 
Organization (WHO) declared the COVID-19 outbreak 
as a Public Health Emergency of International Concern on 
January 31, 2020, but classified it as a pandemic only by 
March 11.4 As of May 19, a total of 4.8 million confirmed 
cases, including 320 000 deaths, have been reported from 188 
countries.5 By then, Europe and The Americas had become 
the new epicentres of the COVID-19 pandemic, with several 
times more SARS-CoV-2 infections and COVID-19 deaths 
compared to China.5
The Outbreak in China
China, where the outbreak was first detected, experienced 
an exponential growth of confirmed COVID-19 cases 
in January 2020.6 The government reacted rapidly and 
implemented massive public health interventions, in 
particular a combination of a range of social distancing and 
other established non-pharmaceutical epidemic control 
measures.7,8 By January 23, an intense lockdown was 
implemented in Wuhan, the early epicentre of the epidemic, 
followed by Hubei province and finally nearly all of China.7 
The lockdown, together with specific interventions in Wuhan 
such as construction of new hospitals and employment of 
several thousand medical doctors from other parts of China, 
constituted the “perhaps most ambitious, agile and aggressive 
disease containment effort in history.”8 Subsequently, the 
number of reverse transcription polymerase chain reaction 
(RT-PCR)-confirmed newly reported COVID-19 cases 
declined substantially within 4 weeks in the whole of China, 
and the number of new autochthonous infections approached 
zero in early March 2020 (Figure 1).9,10 Given these 
developments, control intensities have been progressively 
relaxed in Chinese provinces since February 17, at a time 
when the instantaneous effective reproduction number (Rt) 
had clearly declined below one.11 While from mid-March 
until the end of April all newly confirmed COVID-19 cases 
were reportedly imported, new autochthonous cases occurred 
in Wuhan and in a few other Chinese cities in May, which are 
now subject to intense local control measures (Figure 1).
The Situation in Germany
In Germany, first cases of COVID-19 were seen by the end 
of January 2020.12,13 By May 19, Germany reported a total 
of 175 210 RT-PCR-confirmed SARS-CoV-2 infections, 
including 8007 deaths, which is among the highest number 
of cases in Europe.14 However, a rather low case fatality rate 
is observed in Germany in comparison to other European 
countries with a high number of reported COVID-19 cases 
(Italy, Spain, France, the United Kingdom), which could be 
explained by an early and broad testing strategy, an initially 
younger SARS-CoV-2 infected population due to transmission 
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at carnival meetings and in ski resorts, and a high-capacity, 
high-standard healthcare system.4,14-18 Moreover, COVID-19 
incidence varies largely between the states in Germany, with 
the highest disease burden being reported from the southern 
states Bavaria and Baden-Württemberg.14 In view of the 
rapidly rising case-load and the high case fatality rate in 
neighbouring countries, a partial lockdown was implemented 
and largely respected in Germany on March 22, initially until 
April 19. Compared to the measures taken in China, as well 
as later in Italy and Spain, the German lockdown can be 
considered as moderate with people still having been able 
to move about individually rather freely.4 Still, the results 
look promising; this may have to do with a rather good 
compliance likely supported by the daily broad and fact-
oriented discussion of national and international pandemic 
developments in the German media. The number of newly 
detected COVID-19 cases has consistently declined since 
early April (Figure 2).14 On April 15 – when there were still a 
few thousand new SARS-CoV-2 infections reported every day 
– the German Government announced an extension of the 
partial lockdown until May 3, but with a number of relaxing 
elements to reduce psychosocial consequences and harm to 
the economy. Experts now worry that, with a Rt of about one 
at the time of the decision and not much reduced since, a too 
liberal relaxation may lead to a rapid resurgence of COVID-19 
cases.18,19 A further relaxation has already started on May 3, 
and the intense and controversial discussion about the precise 
course of a safe exit strategy for Germany continues.
Global Developments
In the absence of effective biomedical interventions, the 
global response to the COVID-19 pandemic has been the 
employment of a combination of containment and mitigation 
activities.4,20 The main goals of these public health interventions 
were to flatten the epidemiological curve, to protect the 
high risk groups of elderly people and patients with chronic 
diseases, and in particular to prevent an overwhelming of 
clinical services.21 National responses varied widely, ranging 
from early and intensive surveillance measures, coupled with 
aggressive approaches to find cases and their contacts and 
to isolate and quarantine them (eg, in Taiwan, South Korea, 
Singapore), to a more laissez faire approach sometimes even 
with the idea to rapidly achieve herd immunity as it was 
initially the case in the United Kingdom and as continues 
to be the case in Sweden.22-25 However, with the observation 
of a rapid overwhelming of existing hospital and intensive 
care unit capacities and corresponding high deaths rates in 
Europe, which started in northern Italy and later occurred 
in areas of Spain, France and the United Kingdom, as well 
as the United States, the majority of countries worldwide 
implemented lockdowns.16,25,26 Consequently, there is now an 
intense discussion on the best exit strategies.26
Policy Alternatives for Germany
Germany needs to choose a strategy now that will probably 
lie somewhere in-between two options at either end of a 
range: At one extreme, it could follow the example of China 
and continue the lockdown until the number of SARS-CoV-2 
infections is brought close to zero; the strategy should then be 
to maintain infection rates at very low levels until a vaccine 
becomes available.27 This would likely be possible through 
combining further increased testing for SARS-CoV-2 in 
the population with intensified contact-tracing followed by 
systematic isolation and quarantine measures. Such a strategy 
would later enable a rational relaxation of control measures 
and re-opening of institutions (eg, schools) as has already 
been successful in countries like China, Singapore, Taiwan, 
South Korea, and New Zealand.22,27-29 The economic and 
psychosocial cost of a prolonged lockdown could be very 
high, however.26 At the other extreme, with slightly relaxing 
measures now, Germany might manage to keep the epidemic 
at its present level, which currently looks promising in 
particular when compared to the statistics of its neighbours 
(Figure 2).14 There is a price as well: the German daily 
COVID-19 death figures were already high in March and 
April and – although they have substantially decreased since 
– there remains a certain risk of further substantial mortality 
given the ongoing spread of the virus into older population 
Figure 1. COVID-19 Control Interventions in China and Development of Laboratory-Confirmed Cases From January 20 to May 19, 2020. Abbreviation: COVID-19, 
coronavirus disease 2019.
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groups, in particular into the populations of retirement homes 
and inhabitants of long-term-care facilities.30,31 A resurgence 
of COVID-19 in Germany could result in a cumulative total 
of tens of thousands of deaths over the following months. This 
may be considered as unacceptable and also unethical, even 
if the German health system would be able to cope with such 
high case numbers.4,14,18,26 
Current strategies for COVID-19 control need to be 
continuously adjusted, and new combinations of non-
medical preventive interventions appear to be promising. 
Besides physical distancing and hygiene procedures, use 
of face masks for healthy individuals in the community is 
increasingly considered as a potentially feasible and effective 
intervention to control respiratory viruses including SARS-
CoV-2.32 A policy for mandatory face masking in public 
buildings and public transport has also been intensively 
discussed in Germany and is currently being adopted in the 
whole country. FFP2/3 masks and medical masks should 
continue to be reserved for professional health staff, but 
cloth masks could easily be produced for mass masking 
during the pandemic.32, 33 While there has been some doubt 
and reservation regarding the effectiveness of mass masking, 
there is now increasing support for a likely benefit of such 
an intervention both in Germany and worldwide.34-37 Even 
more importantly, given the obvious local differences in the 
intensity of COVID-19 incidence, control measures should 
be adjusted to local circumstances, in line with the German 
political constitution.38 However, there needs to be a fine 
balance between actions of individual states and communities 
in Germany on the one hand and the federal Government on 
the other to avoid contradictory messages to the population.
Other strategies that have been proposed lack an evidence-
base and seem socially unacceptable. Predominantly, this 
applies to isolating all elderly persons and people with chronic 
diseases while allowing younger and healthy members of 
society to get infected and to develop immunity (leading also 
to the development of herd immunity). It seems unrealistic 
that it would be possible to protect the large at-risk population 
over a prolonged period of time from getting infected. 
Moreover, COVID-19 is causing severe disease and death 
even in a small proportion of previously healthy middle-aged 
adults.8,26,39 
Conclusions
China’s epidemic management provides an important 
experience from which countries such as Germany can learn. 
This is of particular importance as an early availability of 
game-changing drugs against COVID-19 appears to be more 
and more illusionary and as the availability of an effective 
vaccine will likely need another one to two years.40,41 As all 
countries which are currently under lockdown are facing 
the same challenge to keep SARS-CoV-2 infection numbers 
low after relaxing the control measures, the world may be 
able to learn again from the ongoing experience with such 
an exit strategy in China.26,27 This applies in particular to 
Germany, which would risk to lose many of its achievements 
in case of a severe second wave of the epidemic. There is a 
clear limit though: In contrast to China, Germany should 
rely on its established tradition of political and societal 
dialogue. It should continue to involve not only virologists 
and epidemiologists, but social scientists and all population 
segments when making the painful choices that are required 
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